Activation of an Estrogen/estrogen Receptor Signaling by BIG3 Through Its Inhibitory Effect on Nuclear Transport of PHB2/REA in Breast Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2009 Jun 6

PMID 19496786

Citations 33

Authors

Jung-Won Kim

Miki Akiyama

Jae-Hyun Park

Meng-Lay Lin

Arata Shimo

Tomomi Ueki

Yataro Daigo

Tatsuhiko Tsunoda

Toshihiko Nishidate

Yusuke Nakamura

Toyomasa Katagiri

Affiliations

Soon will be listed here.

Abstract

Breast cancer is known to be a hormone-dependent disease, and estrogens through an interaction with estrogen receptor (ER) enhance the proliferative and metastatic activity of breast tumor cells. Here we show a critical role of transactivation of BIG3, brefeldin A-inhibited guanine nucleotide-exchange protein 3, in activation of the estrogen/ER signaling in breast cancer cells. Knocking-down of BIG3 expression with small-interfering RNA (siRNA) drastically suppressed the growth of breast cancer cells. Subsequent coimmunoprecipitation and immunoblotting assays revealed an interaction of BIG3 with prohibitin 2/repressor of estrogen receptor activity (PHB2/REA). When BIG3 was absent, stimulation of estradiol caused the translocation of PHB2/REA to the nucleus, enhanced the interaction of PHB2/REA and ERalpha, and resulted in suppression of the ERalpha transcriptional activity. On the other hand, when BIG3 was present, BIG3 trapped PHB2/REA in the cytoplasm and inhibited its nuclear translocation, and caused enhancement of ERalpha transcriptional activity. Our results imply that BIG3 overexpression is one of the important mechanisms causing the activation of the estrogen/ERalpha signaling pathway in the hormone-related growth of breast cancer cells.

Citing Articles

Pan-cancer structurome reveals overrepresentation of beta sandwiches and underrepresentation of alpha helical domains.

Medvedev K, Schaeffer R, Chen K, Grishin N Sci Rep. 2023; 13(1):11988.

PMID: 37491511 PMC: 10368619. DOI: 10.1038/s41598-023-39273-5.

Recent advances in peptide-based therapeutic strategies for breast cancer treatment.

Li L, Duns G, Dessie W, Cao Z, Ji X, Luo X Front Pharmacol. 2023; 14:1052301.

PMID: 36794282 PMC: 9922721. DOI: 10.3389/fphar.2023.1052301.

PHB2 promotes colorectal cancer cell proliferation and tumorigenesis through NDUFS1-mediated oxidative phosphorylation.

Ren L, Meng L, Gao J, Lu M, Guo C, Li Y Cell Death Dis. 2023; 14(1):44.

PMID: 36658121 PMC: 9852476. DOI: 10.1038/s41419-023-05575-9.

Role of Prohibitins in Aging and Therapeutic Potential Against Age-Related Diseases.

Belser M, Walker D Front Genet. 2021; 12:714228.

PMID: 34868199 PMC: 8636131. DOI: 10.3389/fgene.2021.714228.

PGRMC1 Promotes Progestin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ERα Signaling.

Bai Y, Ludescher M, Poschmann G, Stuhler K, Wyrich M, Oles J Cancers (Basel). 2021; 13(22).

PMID: 34830790 PMC: 8615993. DOI: 10.3390/cancers13225635.

References

Park J, Lin M, Nishidate T, Nakamura Y, Katagiri T . PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006; 66(18):9186-95. DOI: 10.1158/0008-5472.CAN-06-1601. View

Ueki T, Nishidate T, Park J, Lin M, Shimo A, Hirata K . Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene. 2008; 27(43):5672-83. DOI: 10.1038/onc.2008.186. View

Delage-Mourroux R, Martini P, Choi I, Kraichely D, Hoeksema J, Katzenellenbogen B . Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J Biol Chem. 2000; 275(46):35848-56. DOI: 10.1074/jbc.M001327200. View

Montano M, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen B . An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A. 1999; 96(12):6947-52. PMC: 22022. DOI: 10.1073/pnas.96.12.6947. View

Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y . Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas. Oncogene. 2004; 23(32):5551-7. DOI: 10.1038/sj.onc.1207710. View

Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y . Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res. 2002; 9(2):35-45. DOI: 10.1093/dnares/9.2.35. View

Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T . Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol. 2006; 29(4):799-827. View

Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin Y . Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res. 2003; 63(19):6116-20. View

McCracken M, Olsen M, Chen Jr M, Jemal A, Thun M, Cokkinides V . Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007; 57(4):190-205. DOI: 10.3322/canjclin.57.4.190. View

10.

Yager J, Davidson N . Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006; 354(3):270-82. DOI: 10.1056/NEJMra050776. View

11.

Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353(17):1784-92. DOI: 10.1056/NEJMoa050518. View

12.

Kanehira M, Katagiri T, Shimo A, Takata R, Shuin T, Miki T . Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007; 67(7):3276-85. DOI: 10.1158/0008-5472.CAN-06-3748. View

13.

Jackson C, Casanova J . Turning on ARF: the Sec7 family of guanine-nucleotide-exchange factors. Trends Cell Biol. 2000; 10(2):60-7. DOI: 10.1016/s0962-8924(99)01699-2. View

14.

Jones S, Jedd G, Kahn R, Franzusoff A, Bartolini F, Segev N . Genetic interactions in yeast between Ypt GTPases and Arf guanine nucleotide exchangers. Genetics. 1999; 152(4):1543-56. PMC: 1460709. DOI: 10.1093/genetics/152.4.1543. View

15.

Casanova J . Regulation of Arf activation: the Sec7 family of guanine nucleotide exchange factors. Traffic. 2007; 8(11):1476-85. DOI: 10.1111/j.1600-0854.2007.00634.x. View

16.

Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N . Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005; 24(41):6201-12. DOI: 10.1038/sj.onc.1208780. View

17.

Shimo A, Tanikawa C, Nishidate T, Lin M, Matsuda K, Park J . Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 2007; 99(1):62-70. PMC: 11158784. DOI: 10.1111/j.1349-7006.2007.00635.x. View

18.

Cox R, Mason-Gamer R, Jackson C, Segev N . Phylogenetic analysis of Sec7-domain-containing Arf nucleotide exchangers. Mol Biol Cell. 2004; 15(4):1487-505. PMC: 379250. DOI: 10.1091/mbc.e03-06-0443. View

19.

Nishidate T, Katagiri T, Lin M, Mano Y, Miki Y, Kasumi F . Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 2004; 25(4):797-819. View

20.

Kasashima K, Ohta E, Kagawa Y, Endo H . Mitochondrial functions and estrogen receptor-dependent nuclear translocation of pleiotropic human prohibitin 2. J Biol Chem. 2006; 281(47):36401-10. DOI: 10.1074/jbc.M605260200. View